Canine
Enflicoxib (Daxocox) for Canine Osteoarthritis: A Once-Weekly COX-2 Selective NSAID
Bottom line
- Enflicoxib (Daxocox) is a COX-2 selective coxib-class non-steroidal anti-inflammatory drug (NSAID) authorised in the European Union for the treatment of pain and inflammation associated with osteoarthritis in dogs (European Medicines Agency, Daxocox EPAR).
- Its defining practical feature is a once-weekly oral dosing interval after an initial loading dose, in contrast to the daily administration of most canine NSAIDs.
- In a 6-month multicentre field study, the proportion of clinical-sum-score responders was significantly higher with enflicoxib than with placebo at every assessment, and the favourable safety profile seen in earlier shorter studies was maintained over long-term use (Salichs et al. 2024).
- As with all NSAIDs, the safety considerations of the class apply; enflicoxib does not eliminate the need for case selection, monitoring, and attention to gastrointestinal, renal, and hepatic risk.
Drug facts
- Class: COX-2 selective NSAID (coxib class)
- Mechanism: Selective inhibition of cyclo-oxygenase-2, reducing prostaglandin-mediated pain and inflammation (Salichs et al. 2024; EMA Daxocox EPAR)
- Route/interval: Oral; once-weekly maintenance after an initial loading dose (defer to the current product label for figures)
- Indication: Treatment of pain and inflammation associated with osteoarthritis in dogs (EMA Daxocox EPAR)
- Approval: EMA centrally authorised (CVMP positive opinion 19 February 2021; EPAR first published 16 July 2021), product number EMEA/V/C/005354
- Label contraindications and adverse events: Class-typical NSAID precautions apply; consult the current Daxocox product information
A specific patient on enflicoxib?
Get an instant cited answer - no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.
Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=enflicoxib-daxocox-canine-osteoarthritis
What the evidence shows
A weekly-dosed coxib in the canine NSAID landscape
Non-steroidal anti-inflammatory drugs remain the recommended first-line pharmacological treatment for the pain and inflammation of canine osteoarthritis, and several COX-2 selective agents are now available. Enflicoxib is a more recent addition to the coxib class, marketed as Daxocox tablets for dogs (Ecuphar/Animalcare group). The European Medicines Agency lists it under the pharmacotherapeutic group of anti-inflammatory and anti-rheumatic products and describes its authorised indication as the treatment of pain and inflammation associated with osteoarthritis in dogs (EMA Daxocox EPAR).
The clinically distinctive feature of enflicoxib is its dosing schedule: an initial loading dose followed by once-weekly administration. This reflects a long-acting pharmacology and is a departure from the daily dosing typical of most canine NSAIDs. The relevant dosing figures should be taken from the current product label rather than from any secondary summary.
Long-term field efficacy and safety
The pivotal long-term evidence comes from a prospective, multisite, blinded, randomised, placebo-controlled, parallel-group field study (Salichs et al. 2024, Frontiers in Veterinary Science). A total of 109 client-owned dogs with clinical and radiographic signs of osteoarthritis for at least 3 weeks were enrolled, of whom 78 completed all visits. Per the study, dogs were randomised in a 3:1 ratio to enflicoxib or placebo administered once weekly over 6 months, with veterinary assessment by a clinical sum score (CSS) and owner assessment by the Canine Brief Pain Inventory (CBPI).
The percentages of CSS responders for enflicoxib were 71.6, 74.6, and 71.6 percent on days 44, 135, and 189 respectively, each significantly higher than placebo (41.7, 33.3, and 20.8 percent; p less than 0.05 at every timepoint). The owner-assessed treatment response followed the same pattern, reaching significance versus placebo after 2 weeks of treatment.
On safety, the incidence and type of adverse events were as described in earlier, shorter enflicoxib studies and as expected for the NSAID class, with no tendency to increase over the 6-month period, and no relevant changes in haematology, biochemistry, or urine parameters. The authors concluded that the enflicoxib safety and efficacy profile is maintained after long-term treatment, which together with weekly administration makes it a reasonable option for chronic management of naturally occurring canine osteoarthritis.
How weekly dosing fits the clinical conversation
A once-weekly NSAID changes the practical calculus of long-term osteoarthritis management. Owner adherence is a recurrent challenge in chronic canine pain, and a weekly schedule may reduce missed doses compared with daily regimens. At the same time, a long-acting agent means that if an adverse event occurs, the drug cannot simply be stopped the next day and cleared quickly; the pharmacology that enables weekly dosing also implies a longer washout. This trade-off is part of why careful case selection and monitoring remain central to NSAID use regardless of dosing interval.
How this fits clinical practice
Enflicoxib is positioned as one of several COX-2 selective NSAIDs for canine osteoarthritis, distinguished mainly by its weekly dosing and by long-term field data confirming sustained efficacy and class-typical tolerability over 6 months. It does not displace the general principles of NSAID stewardship: baseline assessment, attention to gastrointestinal, renal, and hepatic risk, avoidance of NSAID stacking, and appropriate monitoring. Decisions about whether and how to dose any individual patient should follow the current product label and the clinician's own judgement rather than any figure summarised here. Where a multimodal plan is appropriate, enflicoxib can sit alongside weight management, physical rehabilitation, and adjunctive analgesics, with anti-nerve-growth-factor antibodies and EP4 antagonists as alternative or complementary pharmacological options.
Voyage Clinical Desk
From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.
Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=enflicoxib-daxocox-canine-osteoarthritis
References
- Salichs M, Badiella L, Sarasola P, et al. A blinded, randomized and controlled multicenter field study investigating the safety and efficacy of long-term use of enflicoxib in the treatment of naturally occurring osteoarthritis in client-owned dogs. Frontiers in Veterinary Science. 2024;11:1349901. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1349901/full
- European Medicines Agency. Daxocox (enflicoxib): EPAR - medicine overview. EMEA/V/C/005354. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/daxocox
Changelog
- 2026-06-11: First published.
Related reads
References
More clinical updates
Update (June 11, 2026): Bedinvetmab Improves Activity and Body Composition in Obese Dogs with Osteoarthritis
An April 2026 randomized placebo-controlled trial found bedinvetmab improved objective activity and pain and preserved thigh muscle in obese dogs with osteoarthritis, with no adverse effects reported.
Read →Update (June 11, 2026): RCVS Knowledge Appraisal Rates Grapiprant Osteoarthritis Evidence as Weak
A 2026 RCVS Knowledge critically appraised topic rated the evidence that grapiprant reduces canine osteoarthritic pain as weak: benefit on chronic OA outcomes but no improvement in acute, severe lameness.
Read →Update (June 11, 2026): Pooled Analysis Finds Robenacoxib Safety Comparable to Placebo in Cats with CKD
A pooled analysis of four RCTs found robenacoxib did not significantly raise adverse-event risk versus placebo in cats with chronic musculoskeletal disease, including a 126-cat chronic-kidney-disease subgroup.
Read →Update (June 11, 2026): Long-Term Oclacitinib Well Tolerated for Feline Allergic Pruritus in a 14-Cat Retrospective
A 2025 retrospective of 14 cats found long-term off-label oclacitinib for allergic pruritus well tolerated over a median of 15.5 months, with mild, often transient lab changes and feasible dose reduction in half.
Read →